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Both residual renal and dialytic clearance confer to the
total solute clearance in dialysis patients. Dialytic clearances
of the middle molecule beta-microglobulin (b2M) and the
protein-bound solute p-cresol (pcr) are generally believed
to be higher with peritoneal dialysis (PD) as compared to
hemodialysis (HD). Supportive data, however, are lacking. We
performed a single-center cross-sectional observational study
including 70 unselected patients treated with either high-flux
HD (n¼ 20) or PD (n¼ 50). Mid-day serum levels (PD) and
time-averaged concentrations (HD) of the water-soluble
solutes urea nitrogen, creatinine and phosphate, the middle
molecule b2M, and the protein-bound solute pcr were
determined. Dialytic solute clearances (l/week/1.73 m2)
were calculated from total dialysate collection during the
mid-week session in HD and 24 h dialysate collection in PD.
Renal clearances were calculated for each of the respective
solutes from a timed urine collection. Total clearances were
obtained by summation. HD delivered significantly higher
clearances of all retention solutes studied. This superiority
was especially pronounced for pcr (30.9762.7 vs 4.472.3,
HD vs PD, Po0.0001) and b2M (28.676.6 vs 5.873.1,
HD vs PD, Po0.0001). Renal clearances, conversely, were
significantly higher in patients on PD. Serum levels of all
solutes but pcr were significantly lower in HD than in PD.
Both a higher residual renal function and a lower generation
rate contribute to the lower pcr levels in PD. In conclusion,
superior dialytic clearance of both water-soluble solutes, b2M,
and pcr is achieved by high-flux HD as compared to PD.
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Although renal transplantation offers the best hope to
patients with end-stage renal disease, only a small fraction
of the incident end-stage renal disease population will get
that opportunity, leaving the majority to receive either
hemodialysis (HD) or peritoneal dialysis (PD). Despite
tremendous advances in dialysis technology and considerable
improvements in the delivery of health care, the survival
of dialysis patients who reach end-stage renal disease has
not improved substantially over the last decade.1 For
these patients, defining the optimal dose of dialysis
(dialysis adequacy) and optimal modality strategy remain
critical components of patient management to ensure
optimal survival.
Traditionally, dialysis adequacy has been quantified
referring to the kinetics of urea nitrogen (UN), taken as a
paradigm of all uremic toxins, and applying the principles of
pharmacokinetics using either single- or double-pool variable
volume models (Kt/Vurea).
Recent landmark studies such as the Hemodialysis
(HEMO) and adequacy of dialysis Mexico (ADMEX) trial,
however, failed to demonstrate a benefit on patient survival
by increasing Kt/V urea well above the minimum require-
ments of current American and European guidelines. More-
over, the ADEMEX trial and other studies emphasized the
importance of residual renal function (RRF) as a predictor of
survival in dialysis patients.2–5 Several hypotheses have been
formulated to explain this finding. In the presence of RRF,
the maintenance of an adequate fluid balance is facilitated,
the level of systemic inflammation is lower, and renal
endocrine functions are preserved.6–8 The beneficial impact
of RRF may also be related to the preservation of specific
renal elimination mechanisms such as tubular metabolism
or secretion, which – as has been demonstrated recently – are
crucial for the removal of the middle molecule beta-
microglobulin (b2M) and the protein-bound retention solute
p-cresol (pcr).9,10 Altogether, these findings stimulated
scientist and clinicians to (re)consider middle molecules
and protein-bound retention solutes as useful (additional)
markers of dialysis adequacy. It has been reported that
middle molecules, suppress the appetite, inhibit granulocyte
function, and influence survival independently of small
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molecular solute clearance.11,12 b2M is a major representative
of the middle molecules and is implicated in the formation
of osteoarticular amyloid deposits.13 pcr is considered the
prototype of the protein-bound retention solutes. It has
been demonstrated in vitro to inhibit several biochemical,
biological, and physiological functions.14 Serum concentra-
tions of pcr have recently emerged as a predictor of morbidity
and mortality in HD patients.15,16
It is well known that PD and HD remove about
the same amount of UN17 and phosphate.18 Information
on the performance of PD as compared to high-flux
HD in eliminating pcr and b2M, conversely, is limited
or non-existing. The aim of this cross-sectional observa-
tional study was (i) to compare the clearance of pcr and
b2M in an average (unselected) population of PD and
high-flux HD patients and (ii) to investigate the relative
contribution of dialytic and renal clearances to the
overall clearances.
RESULTS
Patient characteristics
Patient characteristics are depicted in Table 1. The patients
treated with PD were significantly younger and had a
better RRF as compared to the patients on HD. Gender,
renal diagnosis, dialysis vintage, and comorbidity were
similar in the two groups. The total dwell volume and
number of exchanges was significantly higher in patients on
automated peritoneal dialysis (APD) as compared to
continuous ambulatory peritoneal dialysis (CAPD). The
total dwell time, conversely, was significantly longer in
patients on CAPD.
Clearances
Dialytic, renal, and total clearances in patients treated with
HD and PD are summarized in Table 2. HD delivered
significantly higher clearances of all uremic retention solutes
studied. This superiority was especially pronounced for
pcr and b2M and persisted after normalization to dialytic
UN clearances (Figure 1). Renal clearances, conversely,
were higher in patients on PD. As is evident from the
total clearances, the higher renal clearance in PD failed to
compensate for the inferior dialytic clearance for all solutes
but creatinine (Figure 2). Renal clearance was the major route
of elimination of b2M and pcr in patients on PD only.
Dialytic and renal clearances of pcr and b2M were higher in
patients on CAPD as compared to APD. Significance,
however, was not reached.
Serum concentrations
Serum concentrations are summarized in Table 3 and
Figure 3. Serum concentrations of UN, creatinine, phosphate,
and b2M were significantly lower in the patients on HD. pcr
levels, conversely, were significantly lower in patients on
PD. Similar, although somewhat more pronounced differ-
ences between HD and PD were observed in anuric patients.
Significance, however, was lost for pcr (21.8712.8 vs
Table 1 | Patient characteristics
HD APD CAPD Overall ANOVA
n 20 34 16 —
Age (years) 68.8710.9x,y 50.1718.7x 54.2713.8y 0.0007
Male/female 15/5 20/14 9/7 0.4
Renal diagnosis
Cystic 4 4 2 0.8
Diabetic 2 5 1 —
Glomerular 9 10 6 —
Tubulointerstitial 3 6 3 —
Unknown 0 6 3 —
Vascular 2 3 1 —
Dialysis duration (months) 19.3731.5 13.0710.8 12.078.0 0.6
24-h urine output (ml) 2407379x,y 7497645x 7517589y 0.0003
GFR (ml/min/1.73 m2) 1.3972.34x,y 3.2272.61x 4.1672.77y 0.001
Anuria (yes/no) 13/7x,y 7/27x 2/14y 0.0006
Treatment volume (ml) — 11 73572889 900071560 0.001
24-h peritoneal drainage (ml) — 13 22373482 10 46572100 0.009
24-h ultrafiltration volume (ml) — 106671085 135871481 0.4
Icodextrin usage (yes/no) — 15/19 8/8 0.7
PET H/HA/LA/L/missing — 0/7/14/5/8 1/1/3/8/3 0.03
Preceding peritonitis (n) — 0.571.0 0.671.6 0.6
Exchanges (n) — 5.571.1 4.270.5 0.0001
Dwell time (h) — 18.577.3 24.070.0 0.007
Body weight (kg) 59.977.9 67.0714.0 67.9710.4 0.08
BSA (m2) 1.6670.15 1.7670.23 1.7670.18 0.2
Comorbidity (low/medium/high grade) 4/12/4 13/17/4 8/8/0 0.21
Diabetes (yes/no) 2/18 7/27 1/15 0.3
ANOVA, analysis of variance; APD, automated peritoneal dialysis; BSA, body surface area; CAPD, continuous ambulatory peritoneal dialysis; GFR, glomerular filtration rate; PET,
pertioneal equilibration test.
x,yParameters with same suffix differ significantly.
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16.0712.1 mg/l, HD vs PD, P¼ 0.3) Serum concentrations of
pcr were significantly lower in CAPD patients as compared to
APD patients.
Mass removal
Total mass removal (MR) of pcr was significantly higher in
patients on HD as compared to PD. Total MR of creatinine,
conversely, was significantly higher in PD (Figure 4).
Significant differences between APD and CAPD were not
observed (Table 4).
Table 2 | Dialytic, renal, and Clts in HD (n=20), APD (n=34), and CAPD (n=16) patients
HD APD CAPD Overall ANOVA
UN
Clt (l/week/1.73 m2) 140.7731.9x,y 83.1712.4x 102.0732.8y o0.0001
Dialytic clearance (l/week/1.73 m2) 130.8726.9x,y 61.0717.1x 72.4730.9y o0.0001
Dialytic clearance, % of Clt 94. 079.4x,y 74.2719.2x 71.1716.8y o0.0001
Clr (l/week/1.73 m2) 9.8716.0x,y 22.1718.5x 29.5720.0y o0.0001
Clr, % of Clt 6.079.4x,y 25.8719.2x 28.9716.8y o0.0001
Cr
Clt (l/week/1.73 m2) 101.8735.1 84.1726.1 104.0740.7 0.05
Dialytic clearance (l/week/1.73 m2) 83.6718.5x,y 41.8716.0x 49.6719.2y o0.0001
Dialytic clearance, % of Clt 86.9718.2x,y 55.0726.1x 51.8721.4y o0.0001
Clr (l/week/1.73 m2) 18.2731.2x,y 42.2732.9x 54.5738.2y 0.001
Clr, % of Clt 13.1718.2x,y 45.0726.1x 48.2721.4y 0.0001
P
Clt (l/week/1.73 m2) 79.8719.4x 54.8716.1x 65.7720.1 0.0001
Dialytic clearance (l/week/1.73 m2) 68.6715.2x,y 32.7714.8x 40.2713.0y o0.0001
Dialytic clearance, % of Clt 88.9714.8x,y 62.7726.7x 63.0718.3y 0.0003
Clr (l/week/1.73 m2) 10.5714.5y 22.1719.6 25.5718.3y 0.01
Clr, % of Clt 11.1714.8x,y 37.3726.7x 37.0718.3y 0.0003
Pcr
Clt (l/week/1.73 m2) 34.2762.2x 11.478.6x 20.0713.6 0.001
Dialytic clearance (l/week/1.73 m2) 30.9762.7x,y 3.771.7x 5.872.6y o0.0001
Dialytic clearance, % of Clt 88.5719.5x,y 45.5728.9x 40.9726.4y o0.0001
Clr (l/week/1.73 m2) 3.377.8x,y 7.778.5x 14.2713.2y 0.0002
Clr, % of Clt 11.5719.5x,y 54.5728.9x 59.1726.4y o0.0001
b2M
Clt (l/week/1.73 m2) 38.3715.9x,y 18.1714.3x 20.3711.7y o0.0001
Dialytic clearance (l/week/1.73 m2) 28.676.6x,y 5.473.1x 6.573.2y o0.0001
Dialytic clearance, % of Clt 82.4724.1x,y 51.1737.2x 37.3730.1y 0.0001
Clr (l/week/1.73 m2) 9.8715.9y 12.7715.1 16.3711.8y 0.001
Clr, % of Clt 17.6724.1x,y 48.9737.2x 62.7730.1y 0.0001
b2M, b2-microglobulin; ANOVA, analysis of variance; APD, automated peritoneal dialysis; CAPD, continuous ambulatory peritoneal dialysis; Cr, creatinine; Clr, renal clearance;
Clt, total clearance; HD, hemodialysis; pcr, p-cresol; UN, urea nitrogen.
x,yParameters with same suffix differ significantly.
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Figure 1 | Normalized dialytic clearances. &Po0.01, PD vs HD.
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Figure 2 | Total clearances in HD (n¼ 20) and PD (n¼ 50) patients.
&Po0.01, #Po0.0005, and $Po0.0001, respectively, PD vs HD.
Table 3 | Mid-day (PD) and time-averaged (HD) serum con-
centrations in HD (n=20), APD (n=34), and CAPD (n=16)
patients
HD APD CAPD Overall ANOVA
UN (mg/dl) 75.2722.7x,y 108.8723.2x 109.9727.4y o0.0001
Cr (mg/dl) 5.2571.33x,y 7.9672.21x 7.0672.48y o0.0001
P (mg/dl) 3.1270.97x,y 4.9771.40x 4.2070.92y o0.0001
p-Cresol (mg/l) 20.5710.8y 17.079.1x 11.173.8x,y 0.003
b2M (mg/l) 15.375.5x 24.3712.6x 18.879.1 0.02
ANOVA, analysis of variance; APD, automated peritoneal dialysis; CAPD, continuous
ambulatory peritoneal dialysis; HD, hemodialysis; PD, peritoneal dialysis.
x,yParameters with same suffix differ significantly.
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DISCUSSION
Our comparative study, comprising 20 HD and 50 PD
patients, shows significantly higher total clearances of pcr and
b2M during high-flux HD (Figure 2). Considering the
significantly worse RRF in the HD patients, this observation
is striking and clearly demonstrates that high-flux HD
provides superior clearances of pcr and b2M as compared
to PD. It has to be acknowledged that as we did not account
for adsorption, the reported differences in dialytic clearances
between both modalities most probably represent an under-
estimation. Studies comparing the transmembrane transport
of middle molecules and protein-bound solutes in HD and
PD are scarce or non-existing. Because of the high
permeability of the peritoneal membrane, the continuous
nature of the PD treatment, the superior preservation of RRF
in this modality, and supported by clinical data, it has long
been held that removal of middle molecules and protein-
bound solutes is better in PD as compared to HD.19,20 It
should be stressed that most of these clinical studies date
from the 1970s and 1980s, a period were mainly low-flux
cellulose membranes were in use.19–21 In the present study, we
provide strong evidence that with high-flux HD, the opposite
is the case. Our findings thereby extend data previously
reported by Keshaviah.19
Serum levels of UN, phosphate, and b2M were signifi-
cantly lower in HD patients, whereas serum levels of pcr were
significantly lower in PD patients. Generally, serum levels of
uremic retention solutes represent a balance between the rate
of generation and elimination. In steady state, the total MR
may represent an adequate estimation of the generation rate.
This applies to all solutes assessed in the present study but
b2M, which is also metabolized by the kidney to a varying
extent. In agreement with previous studies, we observed
similar MR of UN17 and phosphate18 in patients on PD and
HD. As there are no reasons to assume a different production
rate of b2M in patients on PD and HD, it seems reasonable
to attribute the significantly lower serum concentrations of
UN, phosphate, and b2M in HD to a more efficient removal.
Obviously, b2M concentrations in HD patients reported
in literature over the last two decades show a declining
trend.22–24 This is most probably a reflection of the
introduction of convective therapies and the more wide-
spread use of HD membranes with high efficiency and
permeability.25 In contrast to the other retention solutes
examined, pcr showed a higher generation rate in HD as
compared to PD. This explains the lower serum levels of pcr
in PD, despite the less efficient clearance with this modality.
An increased colonic generation rate of pcr in HD may be the
consequence of impaired protein assimilation26 and/or a
delayed colonic transit.27,28 Differences in diet and bacterial
flora should be accounted for as well.
The two PD modalities were also analyzed separately
(Table 2). A higher dialytic clearance of both b2M and pcr
was observed in patients on CAPD as compared to APD.
Statistical significances, however, was not reached. The
number of exchanges was higher in patients on APD, whereas
the total dwell time was longer in patients on CAPD. Kim
et al.29 recently demonstrated that in contrast to peritoneal
clearance of small molecules, such as creatinine, which is
dependent on the number of exchanges, peritoneal clearance
of middle molecules, such as b2M, depends mainly on the
total dwell hours of PD and not on the number of exchanges
of peritoneal dialysate. Although not formally tested, the same
most probably holds true for the protein-bound retention
solutes. As the ultrafiltration rate was slightly higher in CAPD,
a higher convective transport may also have contributed to the
higher clearance and significantly lower serum concentration
of pcr in the latter treatment modality.30 The epuration
superiority of HD over CAPD was found to be less
pronounced as compared to APD. Indeed, significance
between HD and CAPD was lost for pcr. It remains to be
determined whether this loss of significance is owing to a lack
of power or reflects a real epuration benefit of CAPD over
APD. Additional studies are required to elucidate this issue.
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Figure 3 | Mid-day (PD) and time-averaged (HD) serum concen-
trations in HD (n¼ 20) and PD (n¼ 50) patients. ,* Po0.05 and
$Po0.0001, respectively, PD vs HD.
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Figure 4 | Total MR (mg/week) in HD (n¼ 20) and PD (n¼ 50)
patients. &Po0.01, PD vs HD.
Table 4 | Total mass removal (mg/week) in HD (n=20), APD
(n=34), and CAPD (n=16) patients
HD APD CAPD
Overall
ANOVA
UN 89 349734770 92 025727429 11 1649740506 0.2
Cr 474672009x,y 652271952x 691872572y 0.008
P 23567864 273971042 279071022 0.4
p-Cresol 3517232x 1757108x 2147147 0.003
ANOVA, analysis of variance; APD, automated peritoneal dialysis; CAPD, continuous
ambulatory peritoneal dialysis; HD, hemodialysis.
x,yParameters with same suffix differ significantly.
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A limitation of our study is that mid-week data were
extrapolated to the entire week. However, we assume that the
bias related to the extrapolation is limited as patients were on
the same treatment schedule for at least 4 weeks and were
in stable clinical condition. The extrapolation may result
in a slight underestimation of the ‘true’ weekly dialytic
clearance in HD because of the asymmetric treatment
regimen (3-2-2 day interval). As such, the ‘true’ difference
in dialytic clearances between PD and HD may be even more
pronounced.
Furthermore, it should be emphasized that a rather high
percentage of the PD patients (18%) were anuric at the time
of inclusion. Given the importance of RRF in the overall
clearance of b2M and pcr in PD patients,
9 caution is
warranted when extrapolating the conclusions concerning
the overall clearance of the latter solutes to PD populations
with a better preserved RRF. Finally, we acknowledge that the
kinetic behavior of b2M and pcr may be different from other
members of the class of middle molecules and protein-bound
solutes. These differences may be related to differences in
molecular weight, strength of protein-binding, etc. Caution,
therefore, is warranted when extrapolating our findings to
other retention solutes.
It in unclear to what extent the observed differences in
solute serum level between HD and PD may affect outcome.
Studies in which the mortality rates for patients undergoing
HD were compared with the mortality rates for patients
undergoing PD have yielded conflicting results. Recent
studies lacking the limitations of these earlier studies
consistently show greater relative mortality rates for PD
patients with longer duration of treatment.31,32 Our data
suggest that besides fluid removal, blood pressure control,
and generation of advanced glycation end products, also
clearance of middle molecules and protein-bound solutes
should be considered an explanatory variable.
Conclusion
In the present study, we demonstrate non-equivalence of
dialytic clearance delivered by PD and high-flux HD.
Opposite to prevailing thoughts, we demonstrate superior
dialytic clearance of water-soluble solutes, b2M, and pcr by
high-flux HD as compared to PD. Although these differences,
most probably are not important in the presence of
substantial RRF, they may become clinically relevant when
RRF falls over time.
MATERIALS AND METHODS
Design and subjects
We performed a single-center cross-sectional observational study.
Seventy stable patients (chronic kidney disease stage 5) treated
with dialysis for at least 6 months at the University Hospital
Leuven were included. Twenty subjects were on thrice weekly
high-flux HD and 50 were on PDAPD, n¼ 34; CAPD, n¼ 16).
Patients on PD were free of peritonitis for at least 1 month before
the study. All patients were on the same treatment schedule for at
least 4 weeks and were treated according to current National
Kidney Foundation-Kidney/Dialysis Outcome Quality Initiative
guidelines. Demographic (age, gender, weight, length) and clinical
data (dialysis duration, medication, comorbidity) were collected
by reviewing the medical records. Comorbidity was scored
according to Davies et al.33 and reported as low, medium, or high
grade. The study was approved by the ethical committee of the
University Hospital Leuven and informed consent was obtained
from all patients.
Dialysis procedure, sampling, and calculations
HD. HD was performed using high-flux membranes (F80,
polysulfone, 1.8 m2, Fresenius Medical Care, Germany). All patients
had a native arteriovenous fistula, enabling double-needle vascular
access. Dialysis duration was 23070 min The blood flow was
322.7721.6 ml/min. and dialysate flow was 50070 ml/min. Total
ultrafiltration amounted to 18207824 ml.
For the determination of the renal clearance and MR, urine was
collected during the long interdialytic interval. Renal clearances
(Clr) were calculated as follows:
Clr¼MRr/(Cid*Tid), where MRr is the renal MR, Cid is the
mean of the solute concentration in a blood sample collected
immediately after the HD session that preceded this interval and the
solute concentration in a sample collected before the next HD
session, and Tid is the interdialytic interval time. Renal MR was
calculated by multiplying the urine concentration of the solute with
the collected volume.
For the determination of the dialytic clearance and MR, total
dialysate was collected in a 300-l polyethylene vessel, weighed,
vigorously stirred, and sampled immediately after dialysis. Dialytic
clearances (Cld) were calculated as follows: Cld¼MRd/(Cd*Td),
where MR is the dialytic MR, Cd is the log mean of the pre- and
post-treatment serum levels of the solute, and Td is the actual
dialysis time. Dialytic MR was calculated by multiplying the
dialysate concentration of the solute with the collected volume.
Blood samples were obtained before and immediately after the
dialysis session. Total dialysate collections were performed during
the mid-week dialysis session.
PD. All patients were treated with conventional lactate-buffered
glucose solutions (Dianeal, Baxter, Lessines, Belgium). Details
concerning the treatment regimen are summarized in Table 1.
Fluid balance was maintained by the use of high glucose
concentrated solutions and/or the polyglucose icodextrin during
one long dwell per day (Extraneal, Baxter, Lessines, Belgium).
Peritoneal ultrafiltration was defined as the dialysate outflow minus
the prescribed inflow. The peritoneal membrane transport status
was estimated by means of the pertioneal equilibration test by a
slight modification of the method of Twardowski. Transport
characteristics of the peritoneal membrane were assessed within 12
months of inclusion.
For the determination of MR and clearances, a mid-day blood
sample was taken and total amounts of urine and peritoneal
drainage were collected during the preceding 24-h period, weighed,
and sampled.
Total clearances (Clt) were obtained by summation of Cld and
Clr. MR and clearances were expressed per week of treatment. For
PD patients, the calculated 24-h MR or clearances were multiplied
with seven. For HD patients, dialytic MR or clearances were
multiplied with three. Renal MR and clearances were calculated per
minute of the interdialytic interval and extrapolated to 1 week by
multiplying with 10 080. All clearances were normalized to 1.73 m2
body surface area (l/week/1.73 m2). For comparison purposes, raw
dialytic solute clearances were also normalized to dialytic UN
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clearances by the following equation:
Normalized Cld retention solute
¼ Cld retention solute=Cld urea nitrogen
Residual glomerular filtration rate was estimated by calculating the
arithmetic mean of renal UN and creatinine clearance and expressed
in ml/min/1.73 m2. Anuria was defined as 24-h urine output
o100 ml and/or residual glomerular filtration rate o1 ml/min.
Comparison of serum levels of uremic solutes between PD-and
HD-treated patients was carried out by using mid-day serum levels
in PD patients and time-averaged concentrations in HD patients.
Analytical methods
Urea nitrogen (UN, mg/dl), creatinine (Cr, mg/dl), phosphorus (Ph,
mg/dl) were measured by standard laboratory techniques. b2M (mg/l),
was quantitated by rate nephelometry using an Immage Instrument
(Beckman Coulter, Brea, CA, USA). pcr (mg/l) was analyzed by gas
chromatography mass spectrometry technology, as described elsewhere.34
We and others have recently demonstrated that pcr in human serum is
almost entirely sulfated.34,35 Both pcr and its conjugated metabolites are
quantitated by our analytical procedure.34 In the present paper, we refer
to pcr as the composite of conjugated and unconjugated pcr.
Statistics
Data are expressed as mean7s.d. Differences between HD and PD
and between APD and CAPD were evaluated using the unpaired
Mann–Whitney U-test and w2 test of association for continuous and
categorical data, respectively. Differences between HD, APD, and
CAPD were evaluated by Analysis of variance ( Kruskall–Wallis) with
correction for multiple comparisons (Bonferroni). The SAS version
8.02 (SAS Institute, Cary, NC, USA) software program was used for
the statistical analysis.
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